Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment believe the medication will be effective, but have concerns about the regulatory process used to endorse the drug and are divided over whether the drug is fairly priced at $56,000 a year, according to a new survey from STAT and The Harris Poll.
The responses underscore that the Food and Drug Administration approval this month of the drug, called Aduhelm, has proven divisive among a wide array of experts, and the poll shows the same is true for the U.S. public. Among those who had only heard about the approval, slightly more than half agree the drug will be effective, but were concerned about the FDA process.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
